2024年欧洲内科肿瘤学会（ESMO）年会将于9月13日至17日在西班牙巴塞罗那隆重召开。自ESMO自1975年成立以来，已发展成为拥有35,000多名专业人士的全球肿瘤学权威组织。作为全球规模最大、学术水平最高、最具权威的临床肿瘤学会议之一，众多专家学者将展示肿瘤学领域的最新研究成果，共同推动肿瘤学科的全球发展。

09月13日

Proffered paper session 1: GU tumours, non-prostate
北京时间：20:00
1959O - BL-B01D1, an EGFR x HER3 Bispecific Antibody-drug Conjugate (ADC), in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (UC)
1959O-BL-B01D1，一种EGFR x HER3双特异性抗体-药物偶联物(ADC)在局部晚期或转移性尿路上皮癌(UC)患者中的应用

Dingwei Ye (Shanghai, China)

Proffered paper session: CNS tumours
北京时间：20:00
442O - A phase I clinical trial of intrathecal injection of allogeneic CAR-γδT cells targeting B7H3 for the treatment of patients with recurrent glioblastoma
442O-鞘内注射靶向B7H3的异体CAR-γδT细胞治疗复发性胶质母细胞瘤患者的I期临床试验

Yulun Huang (Suzhou, China)

Mini oral session 1: Haematological malignancies
北京时间：20:00
799MO - The primary results from a randomized double-blind phase II study of rovadicitinib versus hydroxyurea in patients with myelofibrosis
799MO-罗伐昔替尼与羟基脲在骨髓纤维化患者中的随机双盲II期研究的主要结果

Ling Pan (chengdu, China)

800MO - First Report of BCL-2 Inhibitor TQB3909 in Pts with Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) and Acute Myeloid Leukemia (AML): Data From a Phase 1 Study
800MO-BCL-2抑制剂TQB3909用于复发或难治性非霍奇金淋巴瘤(NHL)和急性髓系白血病(AML)患者的首个报告:来自1期研究的数据

Junyuan Qi (Tianjin, China)

801MO - Efficacy and Safety of a Phase 2 Study: Timdarpacept (IMM01) Combined with Azacitidine (AZA) As the First-Line Treatment in Adults with Chronic Myelomonocytic Leukemia (CMML)
801MO-一项2期研究的有效性和安全性：替达派西普（IMM01）联合阿扎胞苷（AZA）作为成人慢性粒细胞白血病（CMML）的一线治疗

Liya Ma (Hangzhou, China)

807MO - High Efficacy and Safety of Interleukin-6-knockdown CD19-targeted CAR T cells in relapsed/refractory B-ALL patients.
807MO-白细胞介素-6敲低CD19靶向CAR T细胞治疗复发/难治性B-ALL患者的高效性和安全性
Lei Yu

Proffered paper session 1: GI tumours, upper digestive
北京时间：22:00
LBA38 - Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy in first-line (1L) treatment of advanced hepatocellular carcinoma (aHCC): a randomized, open-label, phase 2/3 study (DUBHE-H-308)
LBA38-Iparomlimab和tuvonralimab（QL1706）联合贝伐珠单抗和/或化疗用于晚期肝细胞癌（aHCC）的一线（1L）治疗：一项随机、开放标签、2/3期研究（DUBHE-H-308）

Shukui Qin (Nanjing, China)

LBA40 - Primary results from the phase III ALTN-AK105-III-02 study: Anlotinib plus penpulimab versus sorafenib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
LBA40-III期ALTN-AK105-III-02研究的主要结果：安罗替尼联合派安普利与索拉非尼作为晚期肝细胞癌（aHCC）的一线（1L）治疗

Jian Zhou (Shanghai, China)

Lung cancer interception: New approaches to lung cancer screening and prevention
北京时间：22:00
Should we be screening in never smokers for NSCLC?
我们应该在从不吸烟者中筛查非小细胞肺癌吗？

Pan-Chyr Yang (Taipei City, Taiwan)

Proffered paper session 1: Developmental therapeutics
北京时间：22:00
605O - YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase 1 study
605O-YL201，一种新型的B7H3靶向抗体药物偶联物（ADC），用于晚期实体瘤患者（pts）：一项首次人体1期研究的结果

Hongyun Zhao (Guangzhou, China)

Mini oral session: Sarcoma
北京时间：22:00
1722MO - Updated efficacy results of olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and potential mechanisms of action (MOA)
1722MO-奥替尼（HQP1351）治疗琥珀酸脱氢酶（SDH）缺陷型胃肠道间质瘤（GIST）患者的最新疗效结果和潜在作用机制（MOA）

Haibo Qiu (Guangzhou, China)

1724MO - The Final Results of Pulmonary Resectable Metastases of Osteosarcoma With Antiangiogenic and CHemotherapy (PROACH)：An open-label, single-arm phase 2 clinical trial
1724MO-抗血管生成和化疗治疗可切除的骨肉瘤肺转移(PROACH)的最终结果：一项开放标签、单臂2期临床试验

Qiyuan Bao (Shanghai, China)

Mini oral session: NETs and endocrine tumours
北京时间：22:00
1145MO - CVM-005: Phase IIa study of CVM-1118, a novel oral anti-vasculogenic mimicry (VM) agent, in advanced neuroendocrine tumors (NET) after progression on prior therapy
1145MO-CVM-005：新型口服抗血管生成拟态剂CVM-1118在先前治疗进展后的晚期神经内分泌肿瘤（NET）中的IIa期研究

Chia Jui Yen (Tainan City, Taiwan)

ESMO Virtual Plenary revisited
北京时间：22:00
VP1-2024: RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC)
VP1-2024:RATIONALE-315：替雷利珠单抗(TIS)新辅助治疗联合化疗(CT)辅助TIS治疗可切除非小细胞肺癌(NSCLC)的无事件生存期(EFS)和总生存期(OS)

Dongsheng Yue (Tianjin, China)

VP2-2024: Fuzuloparib with or without apatinib in HER2- metastatic breast cancer (mBC) patients (pts) with germline BRCA1/2 mutations (gBRCA1/2m): A randomized phase III trial
VP2-2024：Fuzuloparib联合或不联合阿帕替尼治疗有生殖细胞系BRCA1/2突变(gBRCA1/2m)的HER2转移性乳腺癌(mBC)患者:一项随机III期试验

Huiping Li (Beijing, China)

09月14日

Hot topics in sarcoma
北京时间：14:30
Conclusions and perspectives
结论和展望

Tom Wei-Wu Chen (Taipei City, Taiwan)

Recent breakthroughs in the treatment of endemic NPC 
北京时间：16:15
Changing the treatment paradigm in the treatment of recurrent/metastatic NPC
改变复发/转移性鼻咽癌的治疗模式

Brigette B. Ma (Sha Tin, Hong Kong SAR China)

Mini oral session: NSCLC metastatic
北京时间：16:15
1255MO - A Phase II Safety and Efficacy Study of PM8002/BNT327 in Combination with Chemotherapy in Patients with EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)
1255MO-PM8002/BNT327联合化疗治疗EGFR突变的非小细胞肺癌癌症（NSCLC）的II期安全性和有效性研究

Yi-Long Wu (Guangzhou, China)

EONS Rapid-fire session 1
北京时间：18:00
CN32 - Socioeconomic Status and Cancer: An Umbrella Review and Burden Estimation Study
CN32-社会经济地位和癌症:伞形综述和负担估计研究

Yuxin He (Chengdu, China)

CN78 - The Effects of Lumbar Sympathetic Ganglion Block Therapy on Secondary Lower Limb Lymphedema
CN78-腰交感神经节阻滞治疗继发性下肢淋巴水肿的疗效观察

Hua-Qing Huang (Fuzhou, China)

Treatment of lobular breast cancer (ILC): From pitfalls to opportunities
北京时间：20:45
Local treatment for ILC: Do’s and don’ts
ILC的局部治疗：注意事项

Ava Kwong (Hong Kong, Hong Kong SAR China)

Proffered paper session: Supportive and palliative care
北京时间：20:45
LBA61 - Conventional Oral Morphine vs. IV Patient-Controlled Analgesia (IPCA) with Either Hydromorphone (HM) Continuous Infusion plus Rescue Dose (CIRD) or HM Bolus-Only (BO) for Severe Cancer Pain: a Randomized Phase III Study
LBA61-常规口服吗啡与静脉注射患者对照镇痛（IPCA），使用氢吗啡酮（HM）持续输注加抢救剂量（CIRD）或HM Bolus-Only（BO）治疗严重癌症疼痛：一项随机III期研究

Rongbo Lin (Fuzhou, China)

Mini oral session: GI tumours, lower
北京时间：20:45
514MO - The efficacy and safety of ivonescimab with or without ligufalimab in combination with FOLFOXIRI as first-line (1L) treatment for metastatic colorectal cancer (mCRC)
514MO-依沃西单抗联合莱法利单抗作为转移性结直肠癌癌症（mCRC）的一线（1L）治疗的有效性和安全性

Yanhong Deng (Guangzhou, China)

Targeted therapies in biliary tract cancer: Emerging targets and strategies
北京时间：21:00
Presentation by Expert
专家介绍

Stephen L. Chan (Sha Tin, Hong Kong SAR China)

09月15日

Mini oral session 1: Breast cancer, metastatic
北京时间：14:30
344MO - ESG401, a novel Trop2 antibody-drug conjugate (ADC), and its efficacy evidence in HER2-negative metastatic breast cancer with brain metastases
344MO-ESG401，一种新的Trop2抗体驱动偶联物（ADC）及其在HER2阴性转移性乳腺癌脑转移中的疗效证据

Fei Ma (Beijing, China)

LBA22 - Effects of trastuzumab deruxtecan (T-DXd) vs choice of chemotherapy (TPC) on patient-reported outcomes (PROs) in hormone receptor–positive, HER2-low or HER2-ultralow metastatic breast cancer (mBC): results from DESTINY-Breast06
LBA22-曲妥珠单抗deruxtecan（T-DXd）与化疗选择（TPC）对激素受体阳性、HER2-低或HER2-超低转移性癌症（mBC）患者报告结果（PROs）的影响：来自DESTINY-Breast06的结果

Xichun Hu (Shanghai, China)

Mini oral session: GU tumours, non-prostate
北京时间：14:30
LBA76 - Anlotinib in combined with anti-PD-L1 antibody Benmelstobart(TQB2450) versus sunitinib in first-line treatment of advanced renal cell carcinoma (RCC) -A randomized, open-label, phase III study (ETER100)
LBA76-Anlotinib联合抗PD-L1抗体Benmelstobart（TQB2450）与舒尼替尼在晚期肾细胞癌（RCC）一线治疗中的比较——一项随机、开放标签、III期研究（ETER100）

Xinan Sheng (Beijing, China)

Mini oral session 1: Gynaecological cancers
北京时间：14:30
LBA31 - Cadonilimab plus Chemotherapy ± Bevacizumab as 1L Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer (R/M CC): A Randomized, Double-blind, Placebo-controlled Phase 3 Study (COMPASSION-16)
LBA31-Cadonilimab加化疗±贝伐珠单抗作为持续性、复发性或转移性癌症的1L治疗（R/M CC）：一项随机、双盲、安慰剂对照的3期研究（COMPASION-16）

Xiaohua Wu (Shanghai, China)

Mini oral session: CNS tumours
北京时间：14:30
446MO - SYHA1813, a vascular endothelial growth factor receptor (VEGFR) 1-3/colony-stimulating factor 1 receptor (CSF1R) inhibitor, in patients with recurrent glioblastoma
446MO-SYHA1813，一种血管内皮生长因子受体(VEGFR) 1-3/集落刺激因子1受体(CSF1R)抑制剂，用于复发性胶质母细胞瘤患者

Wenbin Li (Beijing, China)

447MO - A Clinical Study of the Safety and Efficacy of Anlotinib Hydrochloride Combined with Temozolomide dose density scheme for the Treatment of Recurrent High Grade Glioma
447MO-盐酸安罗替尼联合替莫唑胺剂量密度方案治疗复发性高级别胶质瘤的安全性和有效性临床研究

Liang Wang (Xi'an, China)

448MO - A Clinical Study of the Safety and Efficacy of Toripalimab in Combination with Anilotinib for the Treatment of Recurrent Glioblastoma (GBM)
448MO-Toripalimab联合Anilotinib治疗复发性胶质母细胞瘤（GBM）的安全性和有效性临床研究

Liang Wang (Xi'an, China)

453MO - A Phase I study for safety, tolerability, pharmacokinetics, and anti-tumor activity of ABM-1310 in patients (pts) with BRAF V600 mutated recurrent primary brain tumors: interim result
453MO-ABM-1310在BRAF V600突变复发性原发性脑肿瘤患者中的安全性、耐受性、药代动力学和抗肿瘤活性的I期研究：中期结果

Wenbin Li (Beijing, China)

Mini oral session 2: Haematological malignancies
北京时间：14:30
809MO - Efficacy and safety results from the phase 2 study of Timdarpacept in combination with tislelizumab, in prior anti-PD-1 failed classical Hodgkin lymphoma
809MO-Timdarpacept联合替雷利珠单抗治疗既往抗PD-1失败的经典霍奇金淋巴瘤的2期研究的疗效和安全性结果

Yuqin Song (Beijing, China)

810MO - Combination of Mitoxantrone Hydrochloride Liposome with Chidamide in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma: A phase l/II Study
810MO-盐酸米托蒽醌脂质体联合西达本胺治疗复发或难治性外周T细胞淋巴瘤:一项l/II期研究

Zhiming Li (Guangzhou, China)

811MO - An Exploratory Study to Assess the Safety, Immunogenicity, and Preliminary Anti-tumor Activity of the EBV mRNA vaccine (WGc-043 injection) in Patients with NK/T Cell Lymphoma
811MO-评估NK/T细胞淋巴瘤患者EBV mRNA疫苗（WGc-043注射液）的安全性、免疫原性和初步抗肿瘤活性的探索性研究

Xiangrong Song (Chengdu, China)

812MO - Initial Results of the Multicenter Phase 2 Trial of a Novel Hypofractionated Low-dose Radiotherapy for Indolent non-Hodgkin Lymphoma
812MO-一种新型大分割低剂量放疗惰性非霍奇金淋巴瘤的多中心2期试验的初步结果

Xinyue Wang (Beijing, China)

814MO - Molecular Biology Study of Primary Immuno-privileged Lymphomas
814MO-原发性免疫特权淋巴瘤的分子生物学研究

Chen Zhang (Beijing, China)

815MO - A prospective study of orelabrutinib plus obinutuzumab (O2) in treatment-naïve marginal zone lymphoma (MZL): preliminary analysis on efficacy and safety
815MO-奥布替尼联合奥滨尤妥珠单抗(O2)治疗幼稚边缘区淋巴瘤（MZL）的前瞻性研究：疗效和安全性初步分析

Jia-Dai Xu (Shanghai, China)

Proffered paper session: Head and neck cancer
北京时间：16:15
847O - Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase 3 trial
847O-序贯化放疗与诱导化疗+同步化放疗治疗局部区域晚期鼻咽癌的比较:一项多中心、开放标签、非劣效性、随机、3期试验

Chaosu Hu (Shanghai, China)

Medscape Global Oncology - Milestones and Horizons in Hepatobiliary Carcinomas: The Unfolding Story of Immunotherapy
北京时间：19:00
Raising the Bar: Optimizing Curative Opportunities in Early HCC
提高标准：优化早期HCC的治疗机会

Stephen L. Chan (Sha Tin, Hong Kong SAR China)

The Art and Science of Immunotherapy in Clinical Practice: A Case-Based Discussion
临床实践中免疫治疗的艺术与科学：基于案例的讨论

Stephen L. Chan (Sha Tin, Hong Kong SAR China)

Proffered paper session 2: Developmental therapeutics
北京时间：20:45
609O - CLDN18.2 targeted antibody-drug conjugate (ADC), SHR-A1904, in patients (pts) with gastric/gastroesophageal junction cancer (GC/GEJC): a phase 1 study
609O - CLDN18.2靶向抗体-药物偶联物(ADC) SHR-A1904用于胃癌/胃食管结合部癌(GC/GEJC)患者:一项1期研究

Rui-Hua Xu (Guangzhou, China)

Mini oral session 2: Gynaecological cancers
北京时间：20:45
715MO - Safety and Efficacy of Sacituzumab Tirumotecan (sac-TMT) in Patients (pts) with Previously Treated Advanced Endometrial Carcinoma (EC) and Ovarian Cancer (OC) from a Phase 2 Study
715MO-Sacituzumab Tirumotecan (sac-TMT)用于一项2期研究中既往接受过治疗的晚期子宫内膜癌(EC)和卵巢癌(OC)患者的安全性和疗效

Danbo Wang (Shenyang, China)

716MO - Efficacy and Safety of Sacituzumab Tirumotecan (sac-TMT) Plus Pembrolizumab in Patients with Recurrent or Metastatic Cervical Cancer
716MO-Sacituzumab-Tirumotecan（sac-TMT）联合Pembrolizumab治疗复发或转移性癌症宫颈癌患者的有效性和安全性

Xiaohua Wu (Shanghai, China)

717MO - SHR-A1921 in platinum-resistant ovarian cancer (PROC): data from a first-in-human (FIH) phase 1 study
717MO-SHR-A1921治疗铂类耐药卵巢癌症（PROC）：来自首次人内（FIH）1期研究的数据

Dihong Tang (Changsha, China)

720MO - IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced gynecological cancers (Gynecol C): results from a phase 1 study
720MO-IBI354（抗HER2抗体药物偶联物[ADC]）用于晚期妇科癌症（Gynecol C）患者：一项1期研究的结果

Jin Shu (Chongqing, China)

09月16日

Pfizer Oncology - Setting a new benchmark for ALK+ aNSCLC targeted therapy
北京时间：00:30
Welcome and introduction
欢迎和介绍

Tony S.K. Mok (Sha Tin, Hong Kong SAR China)

Optimising 1L treatment in clinical practice
在临床实践中优化1L治疗

Tony S.K. Mok (Sha Tin, Hong Kong SAR China)

ALK+ aNSCLC treatment expectations now and in the future
ALK aNSCL治疗现在和未来的预期

Tony S.K. Mok (Sha Tin, Hong Kong SAR China)

Meeting close
会议结束

Tony S.K. Mok (Sha Tin, Hong Kong SAR China)

Mini oral session: GI tumours, upper
北京时间：14:30
LBA60 - Phase 3 study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA)
LBA60-SHR-1701与安慰剂联合化疗作为HER2阴性胃/胃食管交界处腺癌（G/GEJA）一线（1L）治疗的3期研究

Zhi Peng (Beijing, China)

Mini oral session 2: Breast cancer, metastatic
北京时间：14:30
347MO - The safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triple-negative breast cancer (TNBC)
347MO-依沃西单抗联合化疗作为三阴性乳腺癌（TNBC）一线（1L）治疗的安全性和有效性

Xiaojia Wang (Hangzhou, China)

348MO - A Phase Ib/II Study to Assess the Safety and Efficacy of PM8002/BNT327 in Combination with Nab-Paclitaxel for First Line Treatment of Locally Advanced or Metastatic Triple-Negative Breast Cancer
348MO-评估PM8002/BNT327联合白蛋白结合型紫杉醇用于局部晚期或转移性三阴性乳腺癌一线治疗的安全性和疗效的Ib/II期研究

Yanchun Meng (Shanghai, China)

349MO - Results from a Phase Ia/Ib Study of ESG401, a Novel Trop2 Antibody-Drug Conjugate, in Patients with Different Subtypes of Metastatic Breast Cancer
349MO-ESG401(一种新型Trop2抗体-药物偶联物)治疗不同亚型转移性乳腺癌患者的Ia/Ib期研究结果

Fei Ma (Beijing, China)

320MO - Tibremciclib (BPI-16350) plus fulvestrant in patients with HR+/HER2- advanced breast cancer after progressing on endocrine therapy: A randomized, multicenter, double-blind, phase III study
320MO-内分泌治疗进展后的HR+/HER2-晚期乳腺癌患者接受Tibremciclib(BPI-16350)联合氟维司群治疗:一项随机、多中心、双盲、 III期研究

Shusen Wang (Guangzhou, China)

eHealth and digital innovations
北京时间：16:15
CN12 - Efficacy of Digital Health Intervention in Smoking Cessation: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials
CN12-数字健康干预对戒烟的效果:随机对照试验的系统综述和网络荟萃分析

Shen Li (Chengdu, China)

Mini oral session: Investigational immunotherapy
北京时间：16:15
993MO - A phase 1, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors
993MO-溶瘤病毒OVV-01治疗晚期实体瘤的1期、开放标签、多中心、剂量递增安全性和耐受性研究

Chongren Wang (Shanghai, China)

994MO - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/Rα payloads, in patients with advanced solid tumors
994MO-VG2025是一种表达IL-12和IL-15/Rα有效载荷的非减毒HSV-1溶瘤病毒，在晚期实体瘤患者中进行的1期试验的最新报告

Yinan Shen (Hangzhou, China)

BeiGene - A new comprehensive approach to lung cancer treatment
北京时间：19:00
Single agent IO is the only treatment option for NSCLC with PD-L1 high expression (debate: PRO – M. Reck; CON – T. Mok)
单药IO是PD-L1高表达NSCLC的唯一治疗选择（辩论：PRO-M.Reck；CON-T.Mok）

Tony S.K. Mok (Sha Tin, Hong Kong SAR China)

General panel discussion / audience Q&A
一般小组讨论/观众问答

 Tony S.K. Mok (Sha Tin, Hong Kong SAR China)

Take-home messages and farewell
带回家的信息和告别

Tony S.K. Mok (Sha Tin, Hong Kong SAR China)

Mini oral session 2: Non-metastatic NSCLC
北京时间：20:45
1241MO - Osimertinib (osi) after definitive chemoradiotherapy (CRT) in unresectable (UR) stg III EGFRm NSCLC: Analyses of CNS and distant progression from the Phase 3 LAURA study
1241MO-Osimertinib（osi）在不可切除（UR）stg III EGFRm NSCLC中接受确定性放化疗（CRT）后：来自3期LAURA研究的中枢神经系统和远处进展分析

Shun Lu (Shanghai, China)

1242MO - The addition of belomethason propionate inhalation to radical radiotherapy for patients with locally advanced non-small cell lung cancer: a randomized controlled, open-label phase II study
1242MO-在局部晚期非小细胞肺癌患者的根治性放疗中加入丙酸贝洛米松吸入:一项随机对照、开放标签的II期研究

JIE ZHANG (Shanghai, China)

Proffered paper session: Sarcoma
北京时间：20:45
Invited Discussant LBA78 and LBA79
邀请讨论者LBA78和LBA79

Tom Wei-Wu Chen (Taipei City, Taiwan)

L司举报瓜

某器械公司营销总监被绑架后撕票

P司挖了N司的

扫码加入交流群

40000+行业菁英共同关注

关注行业洞见，订阅并加星